


What is claimed is:

- 5 1. A compound of the formula (I)



wherein

R<sup>1</sup>

is H, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, or C<sub>6</sub>-C<sub>14</sub>-aryl,  
in which alkyl, alkenyl, alkynyl and aryl are unsubstituted or mono- to tri-substituted  
by a radical R<sup>3</sup>,

R<sup>2</sup>

is C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, or C<sub>6</sub>-C<sub>14</sub>-aryl,  
in which alkyl, alkenyl, alkynyl and aryl are unsubstituted or substituted n times by a  
radical R<sup>3</sup>, where n is an integer from 1 to 3, and

R<sup>3</sup>

is -OH, =O, -O-C<sub>1</sub>-C<sub>6</sub>-alkyl, -O-C<sub>2</sub>-C<sub>6</sub>-alkenyl, -O-C<sub>6</sub>-C<sub>14</sub>-aryl, -NH-C<sub>1</sub>-C<sub>6</sub>-alkyl,  
-NH-C<sub>2</sub>-C<sub>6</sub>-alkenyl, -NH[-C(=O)-(C<sub>1</sub>-C<sub>6</sub>-alkyl)], -NH[-C(=O)-(C<sub>6</sub>-C<sub>14</sub>-aryl)], -NH<sub>2</sub> or  
halogen, when R<sup>1</sup> and R<sup>2</sup> are each independently alkyl, alkenyl and alkynyl, and  
when R<sup>1</sup> and R<sup>2</sup> are each independently aryl, R<sup>3</sup> is -OH, -O-C<sub>1</sub>-C<sub>6</sub>-alkyl, -O-C<sub>2</sub>-C<sub>6</sub>-


alkenyl,  $-\text{O}-\text{C}_6-\text{C}_{14}\text{-aryl}$ ,  $-\text{NH}-\text{C}_1-\text{C}_6\text{-alkyl}$ ,  $-\text{NH}-\text{C}_2-\text{C}_6\text{-alkenyl}$ ,  $-\text{NH}[-\text{C}(=\text{O})-(\text{C}_1-\text{C}_6\text{-alkyl})]$ ,  $-\text{NH}[-\text{C}(=\text{O})-(\text{C}_6-\text{C}_{14}\text{-aryl})]$ ,  $-\text{NH}_2$  or halogen, in which alkyl and alkenyl can be further substituted by  $-\text{CN}$ ,  $-\text{amide}$  or  $-\text{oxime}$  functions, and aryl can be further substituted by  $-\text{CN}$  or  $-\text{amide}$  functions,

5  $\text{X}^1$  is  $\text{CH}_2$  or  $\text{O}$ ,

$\text{X}^2$ ,  $\text{X}^3$  and  $\text{X}^4$  independently of one another are  $\text{O}$ ,  $\text{NR}^1$  or  $\text{S}$ ,  
wherein  $\text{R}^1$  is as previously defined,

10 or a stereoisomeric form of the compound of the formula (I) or a mixture of stereoisomers of a compound of the formula (I) in any ratio, or a physiologically tolerable salt of a compound of the formula (I) or a physiologically tolerable salt of a stereoisomeric form of a compound of the formula (I).


15 2. The compound according to claim 1 which is the compound of formula (II)



wherein  $\text{R}^1$ ,  $\text{R}^2$  and  $n$  are as previously defined.

20


3. The compound according to claim 2, which is the compound of formula (III)



(III).

4. A process for the preparation of a compound of the formula (I) according to claim 1 comprising:

- 5 (a) extracting parts of the plant *Garcinia punctata* or one of its variants and/or mutants,  
(b) isolating and optionally purifying a compound of the formula (III),



(III)

- (c) derivatizing the compound of the formula (III), if appropriate using a suitable reagent, to give a compound of the formula (I) and,  
(d) converting the compound of the formula (I), if appropriate, into a pharmacologically tolerable salt.

5. The process according to claim 4 for the preparation of a compound of the formula (II) comprising:

- (a) extracting parts of the plant *Garcinia punctata* or one of its variants and/or mutants,  
(b) isolating and optionally purifying a compound of the formula (III), and

(c) converting the compound of the formula (III), if appropriate, into a pharmacologically tolerable salt.

6. A compound as claimed in claim 1 for the use as a pharmaceutical.

5

7. A method for the treatment or prophylaxis of bacterial infections comprising administering to a patient in need of said treatment an effective amount of a compound according to claim 1 or a pharmacologically tolerable salt thereof.

10 8. A pharmaceutical composition comprising a compound of claim 1 or a pharmacologically tolerable salt thereof and one or more physiologically acceptable excipients.

15 9. A process for the production of a pharmaceutical composition as claimed in claim 8, comprising bringing a compound of the formula I, or a pharmacologically tolerable salt thereof, into a suitable administration form using one or more physiologically suitable excipients.

20